PFE · Pfizer Inc · Financials

$28.89 +0.06 (+0.21%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$164.67B

5.70B

Volume · Nov 13 21.6M Avg daily vol (3M) 33.41M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$62.58B -1.6%

FY2025

Net Income

$7.77B -3.2%

FY2025

Gross Margin

74.33% +2.4pp

FY2025

Diluted EPS

$1.36 -3.5%

FY2025

Operating Cash Flow

$11.7B -8.2%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	-14.8%	+8.5%	—	$60.5B – $62.5B	$63.63B	$62.58B	$63.63B^G	$59.55B^G	$101.18B^G	$81.29B^G	$41.65B	$40.91B	$40.83B	$52.55B	$52.82B	—	—	$51.58B	$54.66B	$61.04B	$65.17B	$49.27B	$48.3B	$48.42B
Net Interest Income	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-$1.01B	-$1.14B	-$1.23B	—	—	—	—
Cost of Revenue	-22.4%	+13.6%	+5.2%	—	$16.94B	$16.07B	$17.85B	$24.95B	$34.34B	$30.82B	$8.48B	$8.05B	$8.99B	$11.23B	$12.32B	$9.65B	$9.58B	$9.59B	$9.82B	$12.5B	$14.79B	$8.46B	$8.11B	$11.24B
Gross Profit	-11.4%	+7.0%	—	—	$46.69B	$46.51B	$45.78B	$34.6B	$66.83B	$50.47B	$33.17B	$32.85B	$31.84B	$41.32B	$40.5B	—	—	$42B	$44.84B	$48.54B	$50.38B	$40.81B	$40.18B	$37.18B
Gross Margin	—	—	—	—	—	74.33%	71.94%	58.1%	66.05%	62.08%	79.63%	80.31%	77.99%	78.63%	76.67%	—	—	81.42%	82.03%	79.52%	77.31%	82.83%	83.2%	76.79%
Research & Development	-3.0%	+3.7%	+3.1%	—	$11.52B	$10.44B	$10.82B	$10.68B	$11.43B	$10.36B	$8.71B	$8.39B	$7.76B	$7.68B	$7.89B	$7.69B	$8.39B	$6.68B	$7.48B	$8.68B	$9.48B	$7.82B	$7.95B	$8.09B
Selling, General & Administrative	+0.3%	+3.5%	-0.7%	—	$13.81B	$13.79B	$14.73B	$14.77B	$13.68B	$12.7B	$11.6B	$12.73B	$12.61B	$14.8B	$14.84B	$14.81B	$14.1B	$14.36B	$15.17B	$17.58B	$18.97B	$14.75B	$14.54B	$15.63B
Amortization of Intangibles	—	—	—	—	—	—	$5.3B	$4.7B	$3.6B	$3.7B	$3.4B	$4.5B	—	—	—	$3.8B	$4.1B	$4.8B	$5.3B	$5.7B	$5.5B	$2.88B	$2.67B	$3.13B
Depreciation & Amortization	+9.2%	+7.1%	+2.5%	—	$6.5B	$6.59B	$7.01B	$6.29B	$5.06B	$5.19B	$4.68B	$5.76B	$6.38B	$6.27B	$5.76B	$5.16B	$5.54B	$6.31B	$7.39B	$8.7B	$8.4B	$4.76B	$5.09B	$5.2B
Restructuring Charges	+7.4%	+15.3%	+3.0%	—	$1.53B	$1.09B	$1.99B	$1.97B	$882M	$741M	$535M	$227M	$796M	$30M	$1.06B	$811M	$170M	$1.04B	$1.43B	$2.12B	—	—	—	—
Interest Expense	+29.2%	+13.0%	+8.3%	—	$2.71B	$2.67B	$3.09B	$2.21B	$1.24B	$1.29B	$1.45B	$1.57B	$1.32B	$1.27B	$1.19B	$1.2B	$1.36B	$1.41B	$1.52B	$1.68B	$1.8B	$1.23B	$516M	—
Interest Income	+33.9%	+52.5%	+2.5%	—	$502M	$603M	$545M	$1.62B	$251M	$36M	$73M	$225M	$333M	$391M	$470M	$471M	$425M	$403M	$382M	$456M	—	—	—	—
Other Non-Operating Income	—	—	—	—	-$9.38B	-$6.72B	-$4.39B	-$222M	-$1.06B	$4.88B	-$1.21B	-$3.5B	-$2.08B	-$1.42B	-$3.79B	-$2.86B	-$1.01B	$532M	-$4.02B	-$139M	$147M	-$62M	-$48M	—
Gain on Sales of Real Estate	—	—	—	—	—	—	-$420M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity in Earnings of Unconsolidated Entities	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$45M	$86M	—	—	—	—	—	—	—
Pretax Income	-40.0%	+1.3%	-1.7%	—	$4.26B	$7.52B	$8.02B	$1.06B	$34.73B	$24.31B	$7.04B	$11.32B	$3.59B	$12.31B	$8.35B	$8.97B	$12.24B	$15.72B	$11.24B	$11.48B	$9.47B	$10.67B	$9.69B	$9.28B
Income Tax	—	—	—	—	$186M	-$266M	-$28M	-$1.12B	$3.33B	$1.85B	$370M	$583M	-$266M	-$9.05B	$1.12B	$1.99B	$3.12B	$4.31B	$2.22B	$3.62B	$1.15B	$2.15B	$1.65B	$1.02B
Net Income	-37.2%	-3.2%	+1.1%	—	$4.03B	$7.77B	$8.03B	$2.12B	$31.37B	$21.98B	$9.16B	$16.03B	$11.15B	$21.31B	$7.22B	$6.96B	$9.14B	$22B	$14.57B	$10.01B	$8.26B	$8.64B	$8.1B	$8.14B
Net Margin	—	—	—	—	—	12.42%	12.62%	3.56%	31.01%	27.04%	21.99%	39.18%	27.32%	40.55%	13.66%	—	—	42.65%	26.66%	16.4%	12.67%	17.53%	16.78%	16.82%
Net Income Attributable to Noncontrolling Interests	+5.4%	+2.6%	+4.7%	—	$36M	$41M	$31M	$39M	$35M	$45M	$36M	$29M	$36M	$47M	$31M	$26M	$32M	$69M	$28M	$40M	$31M	$8M	$23M	$42M
Net Income Available to Common Stockholders	-37.2%	-3.2%	+1.1%	—	$4.03B	$7.77B	$8.03B	$2.12B	$31.37B	$21.98B	$9.16B	$16.03B	$11.15B	$21.31B	$7.21B	$6.96B	$9.13B	$22B	$14.57B	$10.01B	$8.26B	$8.63B	$8.1B	—
Comprehensive Income	-36.1%	-4.8%	+4.7%	—	$5.13B	$7.54B	$8.15B	$2.46B	$28.97B	$21.39B	$9.64B	$15.91B	$9.2B	$23.02B	$5.7B	$4.76B	$5.09B	$24.66B	$12.75B	$9.32B	$4.27B	$13.77B	$1.29B	$10.96B
EPS (Basic) USD/shares	-37.4%	-3.7%	+1.9%	—	$0.72	$1.37	$1.42	$0.38	$5.59	$3.92	$1.65	$2.88	$1.90	$3.57	$1.18	$1.13	$1.44	$3.23	$1.96	$1.28	$1.03	$1.23	$1.20	$1.18
EPS (Diluted) USD/shares	-37.1%	-3.6%	+2.1%	$2.80 – $3.00*	$0.70	$1.36^G	$1.41^G	$0.37^G	$5.47^G	$3.85^G	$1.63	$2.82	$1.87	$3.52	$1.17	$1.11	$1.42	$3.19	$1.94	$1.27	$1.02	$1.23	$1.20	$1.17
Shares Outstanding (Basic Avg) shares	+0.4%	+0.5%	-0.8%	—	—	5.68B	5.66B	5.64B	5.61B	5.6B	5.56B	5.57B	5.87B	5.97B	6.09B	6.18B	6.35B	6.81B	7.44B	7.82B	8.04B	7.01B	6.73B	6.92B
Shares Outstanding (Diluted Avg) shares	-0.1%	+0.3%	-0.9%	—	—	5.71B	5.7B	5.71B	5.73B	5.71B	5.63B	5.68B	5.98B	6.06B	6.16B	6.26B	6.42B	6.9B	7.51B	7.87B	8.07B	7.05B	6.75B	6.94B

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2024: $89.24B in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current debt and lease obligations	2026-09-27	USD 2,674,000,000	10-Q filed 2026-11-03
Current portion of long-term debt	2026-09-27	USD 2,604,000,000	10-Q filed 2026-11-03
Noncurrent debt carrying amount	2026-09-27	USD 59,997,000,000	10-Q filed 2026-11-03

1 filing observation remains unmatched and is excluded from instrument histories.

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

3.40×

Peer median 7.28×

EV/EBIT

—

P/E (TTM)

41.27×

Peer median 45.14×

Price/Sales (TTM)

2.59×

Peer median 6.60×

Price/Book

1.85×

Peer median 8.44×

Peer medians compare against the 12 similar-size Drug Manufacturers - General companies (of 20 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Biopharma Segment	$61,199,000,000	$62,400,000,000	$58,237,000,000	$99,826,000,000	$79,557,000,000	$40,724,000,000	$38,013,000,000
Business Innovation Segment	—	—	$1,310,000,000	$1,342,000,000	$1,731,000,000	$926,000,000	$810,000,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$37,078,000,000	$38,691,000,000	$28,145,000,000	$43,317,000,000	$29,746,000,000	$21,455,000,000	$20,326,000,000	$20,119,000,000
International Developed Markets	$16,188,000,000	$16,057,000,000	$20,910,000,000	$40,534,000,000	—	—	—	—
International Emerging Markets	$9,313,000,000	$8,879,000,000	$10,498,000,000	$17,324,000,000	—	—	—	—
Developed Europe	—	—	—	—	$18,336,000,000	$7,788,000,000	$7,729,000,000	$7,997,000,000
Developed Rest of World	—	—	—	—	$12,506,000,000	$4,036,000,000	$4,022,000,000	$4,090,000,000
Emerging Markets	—	—	—	—	$20,701,000,000	$8,372,000,000	$8,828,000,000	$8,618,000,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Product	$51,663,000,000	$53,816,000,000	$50,914,000,000	$91,793,000,000	—	—	—	—
Royalty	$1,650,000,000	$1,423,000,000	$1,058,000,000	$845,000,000	—	—	—	—
Pfizer Centre One	$1,338,000,000	$1,146,000,000	$1,272,000,000	$1,342,000,000	—	—	—	—
Pfizer Ignite	$41,000,000	$82,000,000	$44,000,000	$7,000,000	—	—	—	—
Paxlovid NDA Labeled US Strategic National Stockpile	—	$442,000,000	—	—	—	—	—	—
Total Alliance Biopharmaceuticals	—	—	—	—	$7,652,000,000	$5,418,000,000	$4,648,000,000	$3,838,000,000
Total Biosimilars	—	—	—	—	$2,343,000,000	$1,527,000,000	$911,000,000	$769,000,000
Total Sterile Injectable Pharmaceuticals	—	—	—	—	$5,746,000,000	$5,315,000,000	$5,013,000,000	$5,173,000,000

Key facts CIK 78003 CUSIP 717081103 13F (30d) 2335 filings 2175 filers Visit website Investor relations